Oxygenta Pharmaceutical Intrinsic Value
Oxygenta Pharmaceutical intrinsic value. Oxygenta Pharmaceutical (OXYGENTAPH) median intrinsic value is ₹61.08 from 1 valuation models (range ₹61–₹61), vs current price ₹47.75 — +27.9% upside (Trading Below Calculated Value), margin of safety 21.8%. Read Oxygenta Pharmaceutical dividend policy for the complete payout history and dividend yield track record.
OXYGENTAPH Valuation Methods Summary — DCF, Graham Number & P/E
Oxygenta Pharmaceutical intrinsic value across 1 models vs current price ₹47.75 — upside/downside and value range per method. Compare with OXYGENTAPH fundamental valuation to assess whether the stock is under or overvalued.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Revenue Multiple Method | revenue | ₹61.08 | ₹54.97 - ₹67.19 | +27.9% | Revenue/Share: ₹30.54, P/S: 2.0x |
OXYGENTAPH Intrinsic Value vs Market Price — All Valuation Models
Oxygenta Pharmaceutical fair value range ₹61–₹61 vs current market price ₹47.75 across 1 valuation models. For current market price and key ratios, visit Oxygenta Pharmaceutical share price chart.
OXYGENTAPH Intrinsic Value Analysis — Undervalued or Overvalued?
Oxygenta Pharmaceutical median intrinsic value ₹61.08, current price ₹47.75 — Trading Below Calculated Value by 27.9%, margin of safety 21.8%.
What is the intrinsic value of OXYGENTAPH?
Based on our comprehensive analysis using 1 different valuation methods, the estimated intrinsic value of Oxygenta Pharmaceutical (OXYGENTAPH) is ₹61.08 (median value). With the current market price of ₹47.75, this represents a +27.9% variance from our estimated fair value.
The valuation range spans from ₹61.08 to ₹61.08, indicating ₹61.08 - ₹61.08.
Is OXYGENTAPH undervalued or overvalued?
Based on our multi-method analysis, Oxygenta Pharmaceutical (OXYGENTAPH) appears to be trading below calculated value by approximately 27.9%.
OXYGENTAPH Financial Health — Key Ratios vs Industry Benchmarks
Oxygenta Pharmaceutical financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.35 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | -3.32 | Industry Standard: <0.5 | Below 0.5 | Indicates financial leverage level |
| Return on Equity | 68.0% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | -24.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.36x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
OXYGENTAPH Cash Flow Quality — Operating & Free Cash Flow
Oxygenta Pharmaceutical operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹3 Cr | ₹-3 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹-13 Cr | ₹-15 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-2 Cr | ₹-7 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-2 Cr | ₹-5 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹-2 Cr | ₹-6 Cr | Negative Cash Flow | 3/10 |